Humacyte Valuation
| HUMAW Stock | USD 1.71 0.24 16.33% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Humacyte retains a regular Real Value of $1.38 per share. The prevalent price of the firm is $1.71. Our model calculates the value of Humacyte from evaluating the firm fundamentals such as Return On Equity of -8.51, net income of (110.78 M), and Return On Asset of -0.53 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Humacyte's price fluctuation is extremely dangerous at this time. Calculation of the real value of Humacyte is based on 3 months time horizon. Increasing Humacyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Humacyte stock is determined by what a typical buyer is willing to pay for full or partial control of Humacyte. Since Humacyte is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Humacyte Stock. However, Humacyte's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.71 | Real 1.38 | Hype 1.47 |
The intrinsic value of Humacyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Humacyte's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Humacyte helps investors to forecast how Humacyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Humacyte more accurately as focusing exclusively on Humacyte's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Humacyte's intrinsic value based on its ongoing forecasts of Humacyte's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Humacyte's closest peers.
Humacyte Cash |
|
Humacyte Valuation Trend
Analysing the historical paterns of Humacyte's enterprise value and its market capitalization is a good way to estimate and gauge the value of Humacyte over time and is usually enough for investors to make rational market timing decisions.
Humacyte Total Value Analysis
Humacyte is currently forecasted to have takeover price of 0 with market capitalization of 0, debt of 58.11 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Humacyte fundamentals before making investing decisions based on enterprise value of the companyHumacyte Asset Utilization
One of the ways to look at asset utilization of Humacyte is to check how much profit was generated for every dollar of assets it reports. Humacyte retains a negative application of resources of -0.53 (percent), losing $0.005323 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Humacyte shows how discouraging it operates for each dollar spent on its resources.Humacyte Profitability Analysis
Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0.About Humacyte Valuation
Our relative valuation model uses a comparative analysis of Humacyte. We calculate exposure to Humacyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Humacyte's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -76.5 M | -72.7 M | |
| Pretax Profit Margin | (6.88) | (7.22) | |
| Operating Profit Margin | (62.15) | (65.26) | |
| Net Profit Margin | 36.93 | 38.78 | |
| Gross Profit Margin | (3.85) | (4.04) |
Humacyte Growth Indicators
Investing in growth stocks can be very risky. If the company such as Humacyte does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 103.4 M |
Humacyte Current Valuation Indicators
Valuation refers to the process of determining the present value of Humacyte and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Humacyte we look at many different elements of the entity such as Humacyte's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Humacyte, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Humacyte's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Humacyte's worth.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.